Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.

In this study, N. sativa oil and decoction significantly protected against chemotherapy-induced alopecia in albino rats.

This study found that using topical minoxidil before and after facelift surgery may help prevent temporal hair loss without increasing other complication risks.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

This study found that combining drug therapy with hair grafts can regress male androgenetic alopecia from Hamilton type V to type III.

This study suggests that combining drugs with hair grafts may effectively regress male androgenetic alopecia from Hamilton type V to type III when evaluated using the Dynamic Multifactorial Classification.

The study explored niosome formulations containing minoxidil and tretinoin and found increased drug stability and controlled release, suggesting potential as an effective drug delivery system for treating hair loss.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This review offers evidence-based recommendations for diagnosing and treating female pattern hair loss, emphasizing clinical assessment and starting treatment with minoxidil, while noting that measurement of certain hormones and vitamins is optional.

The cause of alopecia areata was unknown, and while various treatments existed, no best treatment was agreed upon.

This study provides the most comprehensive review to date of published cases of frontal fibrosing alopecia, emphasizing a notable association with thyroid disease.

This study reports that follicular unit grafting techniques, specifically creating a frontal forelock, achieved excellent and undetectable results in patients with advanced male pattern hair loss, leading to high patient satisfaction.

This study found that methyl nonanoate and methyl caprate significantly enhanced the skin penetration of minoxidil compared to solutions with other common enhancers like Azone, DMSO, or DEET.

In this retrospective study of alopecia areata patients across several European countries, researchers observed a notable reduction in SALT scores, but few patients reached or maintained a clinically significant SALT score of ≤20, indicating potentially limited effectiveness of current treatments for extensive hair loss.

This study formulated a minoxidil-loaded submicron emulsion-based topical gel, which demonstrated effective in vitro release, ex vivo permeation, and stability, suggesting it may offer a targeted treatment approach for alopecia compared to traditional methods.

This study suggests that low-dose oral minoxidil could be a safe and effective option for male and female-patterned hair loss, potentially benefiting those unable to tolerate topical treatments.

This article reviews the diagnosis and management of alopecia areata but reports no new research findings.

This review discusses topical and intralesional treatments for alopecia areata, providing a management strategy based on patient age and disease severity, but reports no new clinical results.

This paper reviews diffuse androgen-dependent alopecia and chronic telogen effluvium in women, highlighting diagnostic challenges and management issues, but reports no new clinical findings; the authors suggest effective treatments are available.

This study investigated a new formula called SV-loaded nanospanlastics for topical application to treat androgenic alopecia. It showed similar effectiveness to minoxidil lotion but with fewer adverse effects when used to enhance dermal delivery and efficacy of sodium valproate.

This study found that petroleum ether extracts of Citrullus colocynthis reduced hair growth initiation time and advanced more hair follicles to the anagen phase in albino rats compared to untreated controls and minoxidil.

This case study reports that a 23-year-old woman with alopecia universalis experienced complete hair regrowth after six months of treatment with tofacitinib, a JAK-3 inhibitor.

PRP treatment for hair loss shows promise, with 58% of patients satisfied and most noticing improvement within 6 months.

This article reviews multiple treatments for alopecia areata, highlighting their variable efficacy and safety without any being curative; it reports no new clinical findings.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

Androgens and other hormones affect hair growth and skin conditions like acne.

This article reviews therapeutic advances published between December 1986 and December 1987 but reports no new research findings; readers are advised to consult the original articles before considering new therapies.

This review discusses current and emerging medical therapies for androgenetic alopecia but reports no new clinical findings, emphasizing the importance of stabilizing the condition as a complement to surgical hair restoration.

This chapter reviews patchy hair loss due to skin disease, nail disorders related to chronic trauma, and treatments for small carcinomas, but it reports no new clinical findings.

The document concludes that proper diagnosis and treatment of nonscarring alopecias can improve quality of life and hair regrowth is possible as the hair follicle remains intact.